CLINICAL ROLE -
Ashley Gallagher is an editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
5 Key Sessions at the American Pharmacists Association Annual Meeting and Exposition
The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.
Read More
Benefits of Empagliflozin Proves Greater Than Placebo for Those With Acute Heart Failure
Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.
Clinical Review Shows Insight on Immune Response of Pain Management Drugs
The findings highlight the potential of acetaminophen, non-steroidal anti-inflammatory drugs, and opioid analgesics to treat infectious diseases.
FDA Approves 10-mg Naloxone Injection to Treat Exposure to Ultra-Potent Weaponized Opioids
Kaléo’s product has received fast-track designation for US military personnel facing this threat on the battlefield.
FDA Accepts Application for Opdivo Plus Chemotherapy for Treatment of NSCLC
Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.
Study: Several FDA-Approved Drugs Help Combat COVID-19 Delta Variant
Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.
Study: Evolocumab Shows a Higher Reduction in LDL-C Than Alirocumab
At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs.
Children Affected by Educational Disruptions Experience Mental Health Declines
During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.
FDA Approves Purdue Pharma’s Nalmefene Hydrochloride Injection to Treat Opioid Overdoses
The agency has given the greenlight to the abbreviated new drug application for the overdose-reversal medication.
FDA Issues 3 Final Pieces of Guidance Regarding Oncology-Related Clinical Trials
The agency addresses the inclusion of older individuals in cancer-studies, the designing and conducting of multiple expansion cohorts, and the expedited development of biologics and drugs.
Keytruda Shows Hint of Major Added Benefit for Patients With Squamous Cell Carcinoma
The median survival time for individuals with SCC and treated with Merck’s pembrolizumab was 13.9 months compared with 8.8 months in the control arm.
Study: Structure of Clostridioides Difficile Provides a New Target for Future Treatments
Links of chain mail are arranged in the bacteria to form a pattern that prevents molecules from entering the cell.
AbbVie Announces Positive Results for Upadacitinib in Patients With Crohn Disease
The drug has achieved both primary endpoints of clinical remission and endoscopic response at week 12 compared with the placebo, the company says.
Studies Show Slightly Elevated Risk of Blood Clots Following COVID-19 Vaccine
The results of 2 analyses in the United Kingdom show a small increase in the potential for intracranial thrombosis after vaccination.
Bariatric Surgery May Reduce Breast Cancer Risk by Half
Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.
Varicella-Zoster Vaccine Reduces Morbidity for Herpes Zoster, Postherpetic Neuralgia
The median duration of discomfort and pain was shorter in the vaccinated group than in the placebo group, at 21 days and 24 days, respectively, investigators say.
Study: Zip Codes Play a Role in COVID-19 Severity
Patients from more socially vulnerable areas were sicker when they arrived at hospitals but did as well as others by the time of discharge, results of a new analysis show.
AstraZeneca Announces Positive Results for Enhertu in Treating HER2 Breast Cancer
Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.
High-Dose IVIG Can Improve Outcomes for Individuals with Severe COVID-19
Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.
Study: T-Cell Responses Directed at Binding Domain of SARS-CoV-2 Increase Protection
Results of the analysis may help inform future COVID-19 vaccine development, investigators say.
FDA Approves Pyrukynd for Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency
The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.
MRIs May Lower Breast Cancer Deaths From Variants in 3 Genes
Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.
Zuranolone Meets Primary Endpoints for Major Depression Disorder in Phase 3 Study
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.
Bristol Myers Squibb Announces Positive Topline Results for Mavacamten
The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.
FDA Accepts sBLA for Breyanzi as Potential Second-Line Treatment of LBCL
The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.
Commission on Opioid Crisis Calls for Changes in Marketing Pharmaceuticals, Managing Care
In the report published by The Lancet, the group provides a brief history of drug use and addiction, describes the opioid landscape, and includes 7 recommendations.
Gilead Announces Positive Results for HIV-1 Treatment Lenacapavir
Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.
AstraZeneca, Merck Announce Positive Results for Lynpaza Plus Abiraterone
The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.
Gilead Says Remdesivir Retains Antiviral Activity Against 10 SARS-CoV-2 Variants
The variants include Alpha, Beta, Gamma, Delta, and Omicron, and the laboratory results are consistent with other analyses.
Study: Risk of Herpes Zoster After mRNA, Inactive COVID-19 Vaccines Increases
But results of analysis show that the positive effects of vaccination still outweigh the potential adverse events.